Answers are grounded in this paper and cite their sources.
The article assesses impact of the angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and angiotensin receptor and neprilysin antagonists in the framework of combined cardial therapy on sSt2, NT-proBNP and Gal-3 levels in patients with stable ischemic heart disease and chronic heart failure of functional classes I–III, having suffered COVID-19 during 12 months of observation
No takes yet. Share an insight, caveat, or question.
Рыжков et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: